论文部分内容阅读
目的：：探讨阿托伐他汀强化降脂治疗对不稳定型心绞痛患者血脂、血清血管性假血友病因子( vWF)与血栓调节蛋白(TM)水平的影响。方法：不稳定型心绞痛患者88例随机分为强化组(n=44)和常规组(n=44)。两组均予以硝酸酯类、阿司匹林肠溶片、β-受体阻断药和低分子肝素等常规治疗。在此基础上,常规组加用阿托伐他汀片20 mg,po,qd,强化组加用阿托伐他汀片40 mg,po,qd。均连用8周。观察两组治疗前后血脂、血清vWF与TM水平变化,比较治疗期间两组心脏缺血相关事件发生率和药品不良反应。结果：治疗8周后,两组患者TC、TG和LDL-C水平均较前明显下降、HDL-C水平则明显上升(P0.05)；两组血清vWF与TM水平较前均有明显下降(P<0.05或0.01),且强化组下降幅度明显大于常规组(P<0.05)。强化组治疗期间心脏缺血相关事件发生率明显低于常规组(P0.05)。结论：阿托伐他汀强化降脂治疗不稳定型心绞痛具有较好的疗效和安全性,能降低心脏缺血相关事件发生率,作用与其降低血脂及血清vWF与TM水平,改善血管内皮细胞功能有关。“,”Objective:To discuss the influence of intensive lipid-lowering therapy by atorvastatin on blood lipid and serum von Wille-brand factor ( vWF) and thrombomodulin ( TM) levels of patients with unstable angina pectoris. Methods: Totally 88 cases of patients with unstable angina pectoris were selected and divided into the intensive group (n=44) and the routine group (n=44) at random. The patients in the two groups were given routine medical treatment, such as nitrates, bayaspirin,β-blocker, low molecular heparin and etc. The patients in the routine group were orally given atorvastatin 20mg, qd, while the patients in the intensive group were given atorvastatin 40mg, qd with the treatment course of 8 weeks. The changes in serum vWF and TM levels in the two groups before and after the medical treatment were observed, and the occurrence rates of cardiac ischemia related events and untoward effect during the medical treatment were compared as well. Results:After the 8-week medical treatment, the levels of TC, TG and LDL-C in the two groups were obviously declined and the levels of HDL-C were obviously increased than those before the treatment (P<0. 05 or P<0. 01), and the declining and increasing rates in the intensive group were much higher than those in the routine group (P<0. 05). The serum vWF and TM levels in the two groups were obviously declined than those before the treatment (P<0. 05 or P<0. 01), and the declining rates in the intensive group were much higher than those in the routine group (P<0. 05). The occurrence rates of cardiac ischemia related events in the inten-sive group during the medical treatment were much lower than those in the routine group (P0. 05). Conclusion:Atorvastatin intensive lipid-lowering has favorable curative effect and security in the treatment of unstable angina pectoris, which can reduce the occurrence rates of cardiac ischemia related events, and the mechanism is related to reducing blood lipid and serum vWF and TM levels and improving the function of vascular endothelial cells.